Background: Studies of the associations between in utero 25-hydroxyvitamin D (25[OH]D) exposure and risk of childhood asthma, wheeze, and respiratory tract infections are inconsistent and inconclusive. Objectives: We sought to assess associations between 25(OH)D levels in cord blood or maternal venous blood and risk of offspring's asthma, wheeze, and respiratory tract infections. Methods: Data were derived from PubMed, Embase, Google Scholar, references from relevant articles, and de novo results from published studies until December 2015. A random-effects meta-analysis was conducted among 16 birth cohort studies. Results: Comparing the highest with the lowest category of 25(OH)D levels, the pooled odds ratios were 0.84 (95% CI, 0.70-1.01; P 5 .064) for asthma, 0.77 (95% CI, 0.58-1.03; P 5 .083) for wheeze, and 0.85 (95% CI, 0.66-1.09; P 5 .187) for respiratory tract infections. The observed inverse association for wheeze was more pronounced and became statistically
Asthma, which is characterized by variable airway obstruction, wheeze, bronchial hyperresponsiveness, and airway inflammation, 1 is very common worldwide and usually starts in childhood. 2 Although allergic constitution, sensitization to allergens, [3] [4] [5] and/or familial history of allergic disease 6 are recognized risk factors for asthma, studies also suggest that maternal vitamin D status during pregnancy can be associated with the risk of asthma in childhood. 7, 8 To date, some birth cohort studies have shown that vitamin D status might play an important role in the development of fetal lungs. [9] [10] [11] Also, epidemiologic studies have suggested that maternal vitamin D intake, 12, 13 as well as vitamin D levels in blood, [14] [15] [16] were inversely associated with respiratory tract infections and other wheezing illnesses, presumably because of its multiple immune effects, including induction of antibacterial responses and modulation of T lymphocytes to suppress inflammation. 17, 18 Data from randomized clinical trials are sparse, but 2 recently published trials reported a nonsignificant more than 20% reduced risk of persistent wheeze/asthma at age 0 to 3 years from prenatal vitamin D supplementation. 19, 20 In addition to the relatively short follow-up period, the investigators acknowledged that the studies might be underpowered.
A systematic review of 3 cohort studies qualitatively summarized the evidence suggesting a potential link between serum levels of vitamin D and the diagnosis of asthma in childhood. 21 Another systematic review of 23 published articles, including 9 cross-sectional, 2 case-control, and 12 cohort studies in both children and adults, suggested that higher serum levels of 25-hydroxyvitamin D (25[OH]D) were associated with lower risk of asthma exacerbations but provided little evidence on whether lower in utero exposure to 25(OH)D has a programming effect on development of asthma in childhood. 22 Notably, neither of these reviews considered wheeze and respiratory tract infections as outcomes.
Because placental transfer of 25(OH)D is the major source of vitamin D in the developing fetus, we conducted this metaanalysis to quantitatively summarize the up-to-date literature to examine the overall associations between 25(OH)D levels of cord 
METHODS

Search strategy and selection criteria
Two investigators (H.F. and P.X.) scrutinized publications independently based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 23 The complete search process is outlined in Fig 1. First, PubMed (1966-) and Embase (1974-) were searched from inception to December 31, 2015 , by using the terms ''vitamin D,'' ''lung disease or asthma or respiratory tract diseases,'' ''epidemiological studies,'' and ''cohort/prospective or follow-up or longitudinal studies.'' Second, Google Scholar was used to search for any other studies that were not identified from the aforementioned literature review. Third, references from the retrieved articles were manually searched for possible additional studies. Conference abstracts and unpublished studies were not included. Finally, to get additional information, we requested de novo data specifically for this meta-analysis from some primary studies. [24] [25] [26] The following inclusion criteria were used in this meta-analysis: (1) English article; (2) prospective birth cohort design; (3) cord blood or maternal venous blood 25(OH)D measurement as exposure; (4) offspring's asthma, wheeze, or respiratory tract infections, which were diagnosed by physicians or met international guidelines or were reported as outcomes by parents; and (5) available data on the relevant odds ratio (OR), relative risk (RR), or hazard ratio and the corresponding 95% CIs.
Quality assessment and data extraction
Two investigators (H.F. and P.X.) independently evaluated the quality of each primary study based on the criteria derived from the Newcastle-Ottawa Scale (NOS) for quality assessment with a maximum score of 9 points. 27 Any discrepancy was adjudicated by a third reviewer (K.H.). The NOS score for cohort studies was divided into 3 groups: selection of cohort (4 points), comparability of cohort (2 points), and assessment of outcome (3 points). The quality of the study was considered high or moderate if the sum score was 8 points or greater or between 5 and 7 points, respectively. We limited our meta-analysis to those studies that were rated as high or moderate quality. One study was excluded from the main analysis because of low quality. 28 Table E1 in this article's Online Repository at www.jacionline.org shows the details of study quality assessment.
Data were extracted from all eligible studies by 2 independent researchers (H.F. and P.X.) based on a standardized form, and any controversy was resolved through consensus by discussion with a third researcher (K.H.). From each included study, we extracted the following information: name of the first author, year of publication, country of origin, study name, proportion of boys, duration of follow-up, numbers of participants/events, exposure assessment and categorization, outcome definition and assessment, adjusted covariates in the final model, and OR/RR/hazard ratio estimates with corresponding 95% CIs for all categories, continuous exposure of interest, or both.
Linear associations were standardized per 10 nmol/L increment in blood 25(OH)D levels to examine the dose-response relationship. If the linear association was not reported in the primary study, we estimated it by using Greenland and Longnecker's generalized least-squares method if the participants and events in each category were available or by using variance-weighted least-squares estimation if this information was unavailable. 29, 30 If the highest exposure category was open ended (eg, >89 nmol/L), its upper limit was determined by assuming its range was the same interval as that of the adjacent category. Twelve of 16 included studies reported ORs (95% CIs). In addition, we obtained de novo data for ORs (95% CIs) from 2 studies, 25, 26 and converted RRs (95% CIs) to ORs (95% CIs) in the other 2 studies 31, 32 by using the following formula:
where P 0 indicated the incidence of the outcome of interest in the nonexposed/ reference group. 33 
Statistical analysis
The ORs and corresponding 95% CIs extracted from individual studies were transformed to natural logarithms to normalize their distribution, stabilize variances, and facilitate calculation of SEs. The pooled ORs and corresponding 95% CIs for each outcome of interest were computed by using a random-effects model by weighting the inverse of variance. To determine the pooled association for risk of asthma and wheeze, we pooled the 2 outcomes within each study first using a random-effects model if the study reported both of the 2 outcomes. The heterogeneity among studies was tested by using the Cochran Q test with a significance level of .10 and quantified by using the I 2 statistic. An I 2 value of 0% to 25%, 26% to 50%, 51% to 75%, or greater than 75% represents very low, low, moderate, or high heterogeneity, respectively. Publication bias was determined by using the Egger regression asymmetry test also with a significance level of .1. The Duval and Tweedie nonparametric ''trim and fill'' method was used to adjust for publication bias, if applicable. 34 Stratified analyses were performed to determine modification effects by a few prespecified factors, including blood source (cord blood vs maternal venous blood), outcome diagnosis (clinician diagnosis vs parental report), and seasonal variation consideration (yes vs no). A random-effects meta-regression model was used to obtain the P value for interaction between each of these factors and the exposure. 35 Sensitivity analyses were conducted to evaluate the influence of replacing a random-effects model with a fixed-effects model and the influence of a single study on the associations by omitting 1 primary study each time in the meta-analysis.
All analyses were performed with STATA statistical software (version 13.0; StataCorp, College Station, Tex). A 2-sided P value of .05 or less was considered statistically significant, if not otherwise specified. Fig 1 shows the flow of the study selection process. A total of 130 articles in PubMed and 356 in Embase were identified initially. Of them, 8 in PubMed (5 reviews and 3 case reports) and 102 in Embase (28 reviews and 74 case reports) were excluded. Also, 111 articles in PubMed and 249 in Embase were excluded after reviewing the title and abstract. Of the 11 studies in PubMed and 5 in Embase, 3 were excluded after full-text review because of substantial overlap with other studies. In addition, 4 studies were found by using Google Scholar. Thus, by systematically searching the literature, 17 studies 10, 11, [24] [25] [26] 28, 31, 32, [36] [37] [38] [39] [40] [41] [42] [43] [44] were identified. After quality assessment, 1 study was excluded. 28 Finally, 16 birth cohort studies were included in this meta-analysis.
RESULTS
Literature search
Study characteristics
Characteristics of the 16 included studies are summarized in Table E2 in this article's Online Repository at www.jacionline. org. These primary studies were conducted in Asia, 38, 40, 43 Europe, 10, [24] [25] [26] 31, 32, 36, 41, 44 North America, 42 and Australia. 11, 37, 39 Of the 16 studies, 10 focused on asthma, including 8871 participants (1494 incident cases) with an average 5.9-year follow-up; 10 studies reported results on wheeze, including 9072 subjects (2277 incident cases) with an average 5.5-year follow-up; and 10 studies presented findings on respiratory tract infections, including 8359 subjects (2562 incident cases) with an average 1.4-year follow-up. Blood 25(OH)D levels were measured with various methods, including chemiluminescence immunoassay, electrochemiluminescence, enzyme immunoassay, HPLC, liquid chromatography-tandem mass spectrometry, HPLC-tandem mass spectrometry, and RIA. Blood samples were of either cord blood or maternal venous blood during pregnancy in different stages. Seven studies were evaluated as high quality, [24] [25] [26] 36, 37, 40, 44 whereas the other 9 studies were evaluated as moderate quality. 10, 11, 31, 32, 38, 39, [41] [42] [43] 
Primary analyses
Asthma. According to available data from 8 studies, 10, 11, [24] [25] [26] 37, 38, 41 a borderline significant inverse association between in utero exposure to vitamin D and risk of asthma in offspring was found. The pooled OR for offspring's asthma was 0.84 (95% CI, 0.70-1.01; P 5 .064), comparing the highest with the lowest category of 25(OH)D levels (Fig 2) . No evidence of heterogeneity (I 2 5 10.4%, P 5 .349) and publication bias (P 5 .308, Egger test) was found.
No statistically significant linear association was observed based on available data derived from 8 studies. 10, [24] [25] [26] 36, 37, 41, 42 The pooled OR for offspring's asthma was 0.99 (95% CI, 16 studies included in the main meta-analysis; one was only included in the sensitivity analysis due to low quality 0.97-1.02; P 5 .691), with a 10 nmol/L increment in 25(OH)D levels. Neither heterogeneity (I 2 5 0.0%, P 5 .520) nor publication bias (P 5 .570, Egger test) was evidenced.
Wheeze. Similar to asthma, a borderline significant inverse association was observed between in utero exposure to vitamin D and risk of wheeze in offspring when combining data from 8 eligible studies. 11, [24] [25] [26] 31, 37, 41, 44 The pooled OR for wheeze was 0.77 (95% CI, 0.58-1.03; P 5 .083), comparing the highest with the lowest category of 25(OH)D levels (Fig 3) . A moderate heterogeneity exists across included studies (I 2 5 62.1%, P 5.010). No publication bias was evident (P 5.122, Egger test).
No statistically significant linear association was determined by using available data from 9 studies. [24] [25] [26] 31, 36, 37, 39, 41, 44 The pooled OR for offspring's wheeze was 0.98 (95% CI, 0.96-1.004; P 5 .114) with every 10 nmol/L increment in 25 The combined results did not reveal a significant inverse association. The pooled OR was 0.85 (95% CI, 0.66-1.09; P 5 .187), comparing the highest with the lowest category of 25(OH)D levels (Fig 4) . There was no evidence on publication bias (P 5 .486, Egger test), but a moderate heterogeneity existed across included studies (I 2 5 66.1%, P 5 .003). A nonsignificant linear association was found. The pooled OR was 0.97 (95% CI, 0.94-1.01; P 5 .156), with a 10 nmol/L increment in 25(OH)D levels. Neither heterogeneity (I 2 5 0.0%, P 5 .495) nor publication bias (P 5 .798, Egger test) existed.
Stratified analysis
We examined potential effect modifications of a few prespecified factors (Table I ). The association with risk of wheeze was Asthma (Highest vs. Lowest) Camargo et al, 2011 37 Morales et al, 2012 41 Pike et al, 2012 25 Magnus et al, 2013 10 Wills et al, 2013 26 Chawes et al, 2014 24 Zosky et al, 2014 11 Chiu et al, 2015 38 Heterogeneity (I 2 = 10.4%, P = .349) Asthma ( Per 10 nmol/L) Camargo et al, 2011 37 Rothers et al, 2011 42 Morales et al, 2012 41 Pike et al, 2012 25 Magnus et al, 2013 10 Wills et al, 2013 26 Baïz et al, 2014 36 Chawes et al, 2014 24 Heterogeneity (I 2 = 0.0%, P = .520) . By contrast, no significant association was found when combining studies with 25(OH)D levels measured in maternal venous blood. Other factors, including outcome diagnosis and seasonal variation consideration, did not appreciably modify the associations of interest. Of note, 1 primary study 11 reported a sex difference. Hence we requested de novo data on sex differences and received data from 3 primary studies. [24] [25] [26] After combining data from these 4 available studies, no significant sex difference was found (data not shown).
Sensitivity analysis
When replacing a random-effects model with a fixed-effects model, the results were generally consistent, except that the association between in utero exposure to 25(OH)D (highest vs lowest) and risk of respiratory tract infection became statistically significant (0.93; 95% CI, 0.91-0.95; P <.001; see Table E3 in this article's Online Repository at www.jacionline.org). Because the most common cause of recurrent wheezing is asthma attacks, we combined these 2 endpoints with available data from 10 studies. 10, 11, [24] [25] [26] 31, 37, 38, 41, 44 The pooled OR was 0.80 (95% CI, 0.66-0.98; P 5 .028), comparing the highest with the lowest category of 25(OH)D levels.
A few studies substantially affect the pooled results (see Table  E4 in this article's Online Repository at www.jacionline.org). The overall association between 25(OH)D levels and asthma was strengthened and became statistically significant when the study by Camargo et al 37 37 Morales et al, 2012 41 Pike et al, 2012 25 Wills et al, 2013 26 Chawes et al, 2014 24 de Jongh et al, 2014 31 Zosky et al, 2014 11 Stelmach et al, 2015 44 Heterogeneity (I 2 = 62.1%, P = .010)
Wheeze ( Per 10 nmol/L)
Camargo et al, 2011 37 Morales et al, 2012 41 Pike et al, 2012 25 Wills et al, 2013 26 Baïz et al, 2014 36 Chawes et al, 2014 24 de Jongh et al, 2014 31 Jones et al, 2015 39 Stelmach et al, 2015 44 Heterogeneity (I 2 = 5.3%, P = .391) 
DISCUSSION
In this meta-analysis we found that increased in utero exposure to 25(OH)D was inversely associated with risk of offspring's wheeze and asthma in childhood, which is in adherence with the findings from 2 recent randomized clinical trials of vitamin D supplementation during pregnancy. The evidence was strengthened when 25(OH)D levels were measured in cord blood. The observed associations were not appreciably modified by sex, outcome diagnosis methods, and seasonal variation consideration in primary studies.
Strengths and limitations
One unique strength of this meta-analysis is that we obtained de novo data from a few primary studies, [24] [25] [26] which provide more accurate and/or additional information specifically for this meta-analysis. Another main strength of this study is that in utero exposure to vitamin D is measured by objective biomarkers (ie, cord blood or maternal venous blood) that are a reflection of the current circulating vitamin D levels obtained from diet and sun exposure. However, we realize that serum 25(OH)D levels might not be the best biomarker; alternative vitamin D biomarkers (eg, tissues and intracellular fluid) are definitely needed in future studies depending on the scale of the study and the budget and ethical considerations.
Despite the above merits, results should be interpreted with caution because of some limitations. First, moderate heterogeneity existed in some pooled analyses. The variations in several factors might generate this heterogeneity. For example, different study population, study location, sample size, duration RTIs (Highest vs. Lowest) Camargo et al, 2011 37 Morales et al, 2012 41 Pike et al, 2012 25 Mohamed et al, 2013 40 Shin et al, 2013 43 Chawes et al, 2014 24 de Jongh et al, 2014 31 Luczynska et al, 2014 32 Stelmach et al, 2015 44 Heterogeneity (I 2 = 66.1%, P = .003)
RTIs ( Per 10 nmol/L)
Camargo et al, 2011 37 Morales et al, 2012 41 Pike et al, 2012 25 Magnus et al, 2013 10 Shin et al, 2013 43 Chawes et al, 2014 24 de Jongh et al, 2014 31 Luczynska et al, 2014 32 Stelmach et al, 2015 44 Heterogeneity (I 2 = 0.0%, P = .495) of follow-up, source of blood samples for measuring vitamin D status, outcome diagnosis, seasonal variation consideration, and adjustment for different covariates in primary studies. In the analyses a random-effects model was used in concordance with the heterogeneity. In addition, stratified analyses were conducted to explore any potential effect modifier.
Second, asthma and respiratory tract infections in some primary studies and wheeze in all studies were reported by parents, except the Copenhagen Prospective Studies on Asthma in Childhood study, 24 in which wheeze was diagnosed at acute visits to the research clinic and by using a daily diary of respiratory symptoms. Although the signs of these health conditions might be clearly visible, the likelihood of misclassification could not be completely ruled out; for example, parents might report wheeze as a respiratory tract infection. Nevertheless, the potential misclassification should not substantially affect our results because the great majority of parental reports were based on a clinician's diagnosis.
Third, maternal 25(OH)D levels in some studies were measured in venous blood during pregnancy at different time points. This inconsistency in the measurement time window might introduce errors in exposure assessment, but this would presumably lead to a bias toward the null. However, most of the studies (12/16) measured 25(OD)D levels in the later stage of pregnancy (ie, 2 studies at 34-week gestation 25, 31 ) or at birth (10 studies 24, 32, [36] [37] [38] [39] [40] [42] [43] [44] ). Thus the different measurement timing in a few studies should not substantially bias our findings.
Fourth, most of the primary studies measured 25(OH)D levels only once, which might not adequately reflect long-term exposure and might attenuate any possible associations of interest because of random variation. Our findings are more likely to suggest a beneficial effect of higher levels of vitamin D in late pregnancy. Further longitudinal studies with repeat measurements of 25(OH) D levels at different stages of pregnancy are warranted.
Fifth, baseline vitamin D levels varied across studies, but we were not able to adjust for this variation in the meta-analysis because of the lack of original data. Sixth, we were not able to pool the data comparing subjects with vitamin D levels of 75 nmol/L or greater with that of all other subjects because of data insufficiency.
Finally, although the pooled analyses were based on fully adjusted models in individual studies, our results might be biased by the inherent limitations in the primary studies, such as residual confounding or confounding from unknown or unmeasured factors.
Comparison with previous studies
In light of the considerable complexity of the pathogenesis of these respiratory outcomes, it is not surprising to see the inconsistency in the available data on vitamin D status and offspring's asthma, wheeze, and respiratory tract infections. One meta-analysis nested in a systematic review based on only 3 birth cohort studies suggested a possible association between low serum vitamin D levels and risk of asthma in children. 21 Another review, which summarized data from 9 cross-sectional, 2 case-control, and 12 cohort studies in both children and adults, suggested that higher serum levels of 25(OH)D were related to lower risk of asthma exacerbations. However, the study did not provide information on the association of in utero exposure to 25(OH)D with the development of asthma in childhood. 22 Notably, neither of these 2 reviews considered wheeze and respiratory tract infections as outcomes. In addition, 1 recent meta-analysis that combined data from 4 cohort studies found that maternal dietary intake of vitamin D was associated with lower odds of offspring's wheeze during childhood. 45 However, dietary intake only accounts for 10% of circulating 25(OH)D.
Findings from the present meta-analysis are generally consistent with those of the previous reviews and provide important additional information on in utero exposure to 25(OH)D and risk of the offspring's wheeze and respiratory tract infections in childhood. Furthermore, the findings are in line with those of 2 recently published randomized clinical trials of vitamin D supplementation during pregnancy, showing a nonsignificant more than 20% reduced risk of persistent wheeze/asthma at age 0 to 3 years. 19, 20 Of note, a recent randomized clinical trial found that maternal or cord blood vitamin D levels should be at least 75 nmol/L to result in reversal or protection of autoimmune effects, 20 but the optimal level during pregnancy for lung and immune maturation is still unknown. In our meta-analysis the distribution of 25(OH)D levels varied across the primary studies, but overall, approximately 28% of participants had 25(OH)D levels of 75 nmol/L or greater (see Table E5 in this article's Online Repository at www.jacionline.org). Thus the pooled results are biologically in concordance with findings from the randomized clinical trials.
Possible explanations
Vitamin D is an immune regulator involved in both cellular and humoral immunity. 46 There are several explanations for the potential beneficial effect of vitamin D on the development of asthma and wheeze, including the following: (1) 25(OH)D can modify T-cell differentiation and dendritic cell activation, 17 which plays an important role in the inflammatory response; (2) 25(OH)D can induce a shift in the profile of cytokine secretion during an immune response to an anti-inflammatory phenotype, with regulatory T lymphocytes predominating in the cell population 47 ; and (3) in macrophages vitamin D can promote antimicrobial responses through induction of antibacterial proteins 18 and stimulation of autophagy and autophagosome activity.
One study demonstrated a very high correlation between maternal and umbilical cord blood vitamin D levels (Spearman correlation 5 0.91), 48 which supports a common belief that 25(OH)D levels measured in maternal venous blood should be parallel to measures in cord blood. However, we found that the association was more pronounced in the studies in which 25(OH)D levels were measured in cord blood. Notably, the heterogeneity of the time window for measuring 25(OH)D levels in maternal venous blood during pregnancy might attenuate any possible associations.
Studies suggest that early lung development differs between boys and girls, 49, 50 which might explain the higher prevalence of asthma in boys than in girls before puberty. 51 Although the present meta-analysis did not observe a sex difference, a potential effect modification of sex cannot be completely ruled out because the available data were derived from a limited number of studies. 11, [24] [25] [26] Because of seasonal variations in UV radiation exposure, seasonal variation in vitamin D status is recognized. 52 One study found that vitamin D deficiency was marginally associated with J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 an increased risk of lower respiratory tract infections in children born in the fall but not in children born in the other 3 seasons. 32 Some but not all primary studies considered vitamin D seasonal variation in the analysis. This inconsistency might affect the pooled results, contribute to the heterogeneity, or both. Nevertheless, seasonal variation consideration did not materially modify the associations of interest in this meta-analysis.
Conclusion
This meta-analysis of birth cohort studies accumulates evidence supporting that increased in utero exposure to 25(OH) D is inversely associated with the risk of asthma and wheeze during childhood. These findings are in keeping with the results of 2 recently published randomized clinical trials of vitamin D supplementation during pregnancy, showing a more than 20% reduced risk of persistent wheeze/asthma at age 3 years.
Key messages
d Two recent randomized clinical trials suggest a nonsignificant protective effect of prenatal vitamin D supplementation on the risk of persistent wheeze/asthma in early childhood. However, the trials might be underpowered.
d After meta-analyzing data from 16 birth cohorts, we show that increased in utero exposure to 25(OH)D is inversely related to risk of offspring's asthma and wheeze but not respiratory tract infections.
